IN2014CN04676A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04676A IN2014CN04676A IN4676CHN2014A IN2014CN04676A IN 2014CN04676 A IN2014CN04676 A IN 2014CN04676A IN 4676CHN2014 A IN4676CHN2014 A IN 4676CHN2014A IN 2014CN04676 A IN2014CN04676 A IN 2014CN04676A
- Authority
- IN
- India
- Prior art keywords
- general formula
- compounds
- prodrugs
- solvates
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides compounds of the general formula (I) their salts and N oxides and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa so that they are useful in the prevention of and/or therapy for thromboembolic diseases.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1122139.7A GB2497806A (en) | 2011-12-21 | 2011-12-21 | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
GB201217290A GB201217290D0 (en) | 2012-09-27 | 2012-09-27 | Compounds |
PCT/GB2012/053217 WO2013093484A1 (en) | 2011-12-21 | 2012-12-20 | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04676A true IN2014CN04676A (en) | 2015-09-18 |
Family
ID=47553259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4676CHN2014 IN2014CN04676A (en) | 2011-12-21 | 2012-12-20 |
Country Status (23)
Country | Link |
---|---|
US (2) | US9732085B2 (en) |
EP (2) | EP2794597B1 (en) |
JP (2) | JP6137193B2 (en) |
KR (1) | KR102011534B1 (en) |
CN (1) | CN104136431B (en) |
AU (1) | AU2012356374B2 (en) |
BR (1) | BR112014015669B1 (en) |
CA (1) | CA2859604C (en) |
DK (1) | DK2794597T3 (en) |
ES (2) | ES2765891T3 (en) |
HK (1) | HK1198386A1 (en) |
HU (1) | HUE036010T2 (en) |
IL (1) | IL233154A (en) |
IN (1) | IN2014CN04676A (en) |
MX (1) | MX351471B (en) |
NO (1) | NO2794597T3 (en) |
PH (1) | PH12014501365A1 (en) |
PL (1) | PL2794597T3 (en) |
PT (1) | PT2794597T (en) |
RU (1) | RU2630677C2 (en) |
SG (1) | SG11201403402VA (en) |
TW (1) | TWI613199B (en) |
WO (1) | WO2013093484A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940720B2 (en) | 2010-02-11 | 2015-01-27 | Bristol-Myers Squibb Company | Macrocycles as factor XIa inhibitors |
US9062061B2 (en) * | 2011-07-13 | 2015-06-23 | Santen Pharmaceutical Co., Ltd. | Compound having PARP inhibitory activity |
EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9079929B2 (en) | 2011-10-14 | 2015-07-14 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
LT2766346T (en) | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
CN104136431B (en) * | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | Pyridone and pyrimidone derivatives as plasma thromboplastin antecedent a inhibitor |
TW201332989A (en) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | Heteroaryls and uses thereof |
TW201416362A (en) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | 1-(cycloalkylcarbonyl)proline derivatives |
RS55975B1 (en) | 2012-08-03 | 2017-09-29 | Bristol Myers Squibb Co | Dihydropyridone p1 as factor xia inhibitors |
CA2880898A1 (en) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
DK2906551T3 (en) | 2012-10-12 | 2018-05-22 | Bristol Myers Squibb Co | CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR |
JP6479763B2 (en) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors |
WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
TWI633089B (en) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | Substituted oxopyridine derivatives |
US9475809B2 (en) * | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
US9765070B2 (en) * | 2013-10-30 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2015116886A1 (en) * | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
NO2760821T3 (en) | 2014-01-31 | 2018-03-10 | ||
WO2015123093A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
WO2015123091A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
CN105829298B (en) * | 2014-02-14 | 2019-02-01 | 四川海思科制药有限公司 | A kind of pyridone or pyrimidone derivatives, and its preparation method and application |
EP3134408B1 (en) | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
WO2016011940A1 (en) * | 2014-07-25 | 2016-01-28 | 江苏恒瑞医药股份有限公司 | Indole-amide derivative, preparation method therefor and application thereof in medicine |
WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
ES2714283T3 (en) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrocycles of diamide that are inhibitors of FXIa |
CN104311537B (en) * | 2014-09-19 | 2016-08-24 | 广东东阳光药业有限公司 | Containing pyrimidone acetyl substituents pyrazole compound and combinations thereof thing and purposes |
WO2016046164A1 (en) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
EP3197896B1 (en) * | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
NO2721243T3 (en) * | 2014-10-01 | 2018-10-20 | ||
WO2016093285A1 (en) * | 2014-12-10 | 2016-06-16 | 小野薬品工業株式会社 | Dihydroindolizinone derivative |
RU2649141C2 (en) * | 2015-04-20 | 2018-03-30 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 3,4-dimethyl-6-(3-pyridyl)-n-phenyl-2-oxo-1,2,3,6-tetrahydropyrimidine-5-carboxamide with antifungal activity against the candida albicans strain |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
JO3703B1 (en) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | Substituted oxopyridine derivatives |
RU2653511C2 (en) * | 2015-07-29 | 2018-05-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) | 4-methyl-n-2,4-dimethylphenyl-6-(3-fluorophenyl)-2-thyoxo-1,2,3,6-tetragydropyrimidine-5-carboxamide that has analgetic action |
EP3331872B1 (en) | 2015-08-05 | 2019-09-25 | Bristol-Myers Squibb Company | Novel substituted glycine derived fxia inhibitors |
CN106496249B (en) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | Oxazoloindole derivative, preparation method and medical application thereof |
US10344039B2 (en) * | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
MX2018005045A (en) | 2015-10-29 | 2018-08-01 | Merck Sharp & Dohme | FACTOR XIa INHIBITORS. |
JP6992284B2 (en) * | 2016-06-06 | 2022-01-13 | 小野薬品工業株式会社 | Pharmaceutical composition containing dihydroindridinone derivative |
EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
CN113912586B (en) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines |
EP3305538A1 (en) | 2016-10-07 | 2018-04-11 | Mitsubishi HiTec Paper Europe GmbH | Heat sensitive recording material |
WO2018065330A1 (en) | 2016-10-07 | 2018-04-12 | Mitsubishi Hitec Paper Europe Gmbh | Heat-sensitive recording material |
CN106950319B (en) * | 2017-04-20 | 2019-08-30 | 西安科技大学 | A method of detection spy's Lu Quban optical isomer content |
CN109507345B (en) * | 2017-09-15 | 2022-08-05 | 万特制药(海南)有限公司 | Rivastigmine bitartrate intermediate and separation and determination method of impurities thereof |
US11299462B2 (en) | 2018-02-27 | 2022-04-12 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of oxopicolinamide derivative and preparation method therefor |
EP3822264A4 (en) | 2018-07-02 | 2021-11-10 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal forms of oxypyridine amide derivative and preparation method therefor |
TWI825144B (en) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | Transglutaminase 2 (tg2) inhibitors |
WO2020094156A1 (en) * | 2018-11-11 | 2020-05-14 | 上海海雁医药科技有限公司 | Diheterocycle-substituted pyridine-2(1h)-ketone derivative, preparation method therefore and pharmaceutical use thereof |
BR112021010476A2 (en) * | 2018-11-30 | 2021-08-24 | Ono Pharmaceutical Co., Ltd. | New crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1h-imidazol-5-yl]-7-[5-chloro-2-(1h) -tetrazol-1-yl)phenyl]-2,3-dihydroindolizin-5(1h)-one |
CN109836360B (en) * | 2019-03-19 | 2021-08-13 | 南京恩泰医药科技有限公司 | Preparation method of edoxaban tosylate intermediate and intermediate compound |
CN112028877B (en) * | 2019-06-04 | 2021-11-26 | 江西济民可信集团有限公司 | Alkoxy pyridone compound and preparation method and application thereof |
WO2020259668A1 (en) * | 2019-06-28 | 2020-12-30 | 上海济煜医药科技有限公司 | Tricyclic compound, preparation method therefor and use thereof |
CN116120240A (en) | 2019-09-27 | 2023-05-16 | 深圳信立泰药业股份有限公司 | FXIa inhibitor compound, preparation method and medical application thereof |
CN112778277B (en) * | 2019-11-11 | 2024-04-02 | 江西济民可信集团有限公司 | Cyclic ketone pyridone biaryl compound, preparation method and application thereof |
CN116133660A (en) * | 2020-07-22 | 2023-05-16 | 詹森药业有限公司 | Compounds useful as factor XIa inhibitors |
WO2023002984A1 (en) * | 2021-07-20 | 2023-01-26 | 小野薬品工業株式会社 | Method for producing imidazole compound |
US20230097157A1 (en) * | 2021-07-22 | 2023-03-30 | Janssen Pharmaceutica Nv | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors |
US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
CN113735770B (en) * | 2021-09-30 | 2023-06-06 | 四川大学 | Method for synthesizing 1-aminoisoquinoline skeleton by rhodium-catalyzed 4-phenyl oxadiazolone and vinylene carbonate |
TWI833610B (en) * | 2022-03-21 | 2024-02-21 | 大陸商上海濟煜醫藥科技有限公司 | Method and intermediates for preparing tricyclic compounds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0042675A1 (en) | 1980-06-20 | 1981-12-30 | Norton Company | Method of mounting a grinding wheel on a spindle |
EP0224283A3 (en) | 1982-05-18 | 1988-09-21 | University Of Florida | Brain-specific drug delivery |
CA1241120A (en) | 1985-10-01 | 1988-08-23 | Sami A. Aly | Alternate mark inversion (ami) receiver |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
EP0407342A3 (en) * | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
DE4221583A1 (en) * | 1991-11-12 | 1993-05-13 | Bayer Ag | SUBSTITUTED BIPHENYLPYRIDONE |
DE4407488A1 (en) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Use of bi:phenylyl-methyl- or phenyl-pyridyl-methyl- pyridone cpds. |
ES2334990T3 (en) | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | PIRIDINONES REPLACED AS MODULATORS OF P38 MAP QUINASA. |
CN1867560A (en) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR20070063044A (en) | 2004-10-15 | 2007-06-18 | 아스트라제네카 아베 | Quinoxalines as b-raf inhibitors |
ES2380632T3 (en) | 2004-11-24 | 2012-05-17 | Vertex Pharmceuticals Incorporated | Acid derivatives3- (2- (3-ACILAMINO-2-OXO-2H-PIRIDIN) -ACETILAMINO) -4-OXO-PENTANOICO and its use as caspase inhibitors |
CA2615574A1 (en) | 2005-07-29 | 2007-02-08 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
EA014245B1 (en) | 2005-12-14 | 2010-10-29 | Бристол-Маерс Сквибб Компани | Arylpropionamide, arylacrylamide, arylpropynamide or arylmethylurea analogs as factor xia inhibitors |
ES2365815T3 (en) * | 2005-12-14 | 2011-10-11 | Bristol-Myers Squibb Company | ANALOGS OF ARILPROPIONAMIDA, ARILACRILAMIDA, ARILPROPINAMIDA OR ARILMETILUREA AS INHIBITORS OF THE XIA FACTOR. |
JP2010510962A (en) * | 2006-11-24 | 2010-04-08 | 武田薬品工業株式会社 | Heteromonocyclic compounds and uses thereof |
WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
CA2708151A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
JP5537442B2 (en) * | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Pyridazine derivatives as factor XIA inhibitors |
EA019685B1 (en) | 2009-02-06 | 2014-05-30 | Янссен Фармасьютикалз, Инк. | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
EP2625170A1 (en) * | 2010-10-07 | 2013-08-14 | Takeda Pharmaceutical Company Limited | 1,4-oxazepane derivatives |
CN104136431B (en) * | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | Pyridone and pyrimidone derivatives as plasma thromboplastin antecedent a inhibitor |
-
2012
- 2012-12-20 CN CN201280070352.3A patent/CN104136431B/en not_active Expired - Fee Related
- 2012-12-20 RU RU2014129797A patent/RU2630677C2/en active
- 2012-12-20 DK DK12813423.6T patent/DK2794597T3/en active
- 2012-12-20 JP JP2014548196A patent/JP6137193B2/en active Active
- 2012-12-20 ES ES17193874T patent/ES2765891T3/en active Active
- 2012-12-20 PL PL12813423T patent/PL2794597T3/en unknown
- 2012-12-20 MX MX2014007269A patent/MX351471B/en active IP Right Grant
- 2012-12-20 ES ES12813423.6T patent/ES2655669T3/en active Active
- 2012-12-20 US US14/366,396 patent/US9732085B2/en active Active
- 2012-12-20 KR KR1020147016952A patent/KR102011534B1/en active IP Right Grant
- 2012-12-20 TW TW101148629A patent/TWI613199B/en not_active IP Right Cessation
- 2012-12-20 PT PT128134236T patent/PT2794597T/en unknown
- 2012-12-20 HU HUE12813423A patent/HUE036010T2/en unknown
- 2012-12-20 AU AU2012356374A patent/AU2012356374B2/en not_active Ceased
- 2012-12-20 EP EP12813423.6A patent/EP2794597B1/en active Active
- 2012-12-20 SG SG11201403402VA patent/SG11201403402VA/en unknown
- 2012-12-20 WO PCT/GB2012/053217 patent/WO2013093484A1/en active Application Filing
- 2012-12-20 BR BR112014015669-7A patent/BR112014015669B1/en not_active IP Right Cessation
- 2012-12-20 CA CA2859604A patent/CA2859604C/en active Active
- 2012-12-20 NO NO12813423A patent/NO2794597T3/no unknown
- 2012-12-20 EP EP17193874.9A patent/EP3290413B9/en not_active Not-in-force
- 2012-12-20 IN IN4676CHN2014 patent/IN2014CN04676A/en unknown
-
2014
- 2014-06-16 PH PH12014501365A patent/PH12014501365A1/en unknown
- 2014-06-16 IL IL233154A patent/IL233154A/en active IP Right Grant
- 2014-11-25 HK HK14111900.0A patent/HK1198386A1/en not_active IP Right Cessation
-
2017
- 2017-05-01 JP JP2017091408A patent/JP6447660B2/en not_active Expired - Fee Related
- 2017-07-07 US US15/644,655 patent/US10717738B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04676A (en) | ||
PH12017502141A1 (en) | Compounds and their methods of use | |
PH12014502573A1 (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
MX2015011897A (en) | Prodrugs of fumarates and their use in treating various deseases. | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
IN2014KN00769A (en) | ||
MX355728B (en) | Kinase inhibitors. | |
IN2014DN10670A (en) | ||
IN2014CN02805A (en) | ||
IN2014CN02806A (en) | ||
MX2013009873A (en) | Tricyclic inhibitors of kinases. | |
MX352975B (en) | Pyridine-and pyrazine derivatives. | |
MX364602B (en) | Selective glycosidase inhibitors and uses thereof. | |
IN2015DN00598A (en) | ||
UA111744C2 (en) | REPLACED PYRIDOPORASINS AS SYK INHIBITORS | |
PH12015501038A1 (en) | Inhibitors of iap | |
GB201209587D0 (en) | Therapeutic compounds | |
IN2014MN01465A (en) | ||
MX362879B (en) | Novel uses. | |
IN2014MN01486A (en) | ||
EA201391586A1 (en) | 17α-HYDROXYLASE / C-LIAZ INHIBITORS | |
IN2014DN08443A (en) | ||
TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |